Neonatal diabetes mellitus;Diabetes melito neonatal

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 2, 2008, Pages 181-187

  Gurgel, Lucimary C ^a   Moisés, Regina S ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Genetic; Neonatal diabetes; Therapeutic

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIDIABETIC AGENT; HOMEODOMAIN PROTEIN; INSULIN; INSULIN PROMOTER FACTOR 1; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; TOLBUTAMIDE; TRANSACTIVATOR PROTEIN;

DIABETES MELLITUS; GENETICS; HUMAN; MUTATION; NEWBORN; REVIEW;

DIABETES MELLITUS; HOMEODOMAIN PROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; INSULIN; KATP CHANNELS; MUTATION; POTASSIUM CHANNELS, INWARDLY RECTIFYING; TOLBUTAMIDE; TRANS-ACTIVATORS;

EID: 43249106494     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302008000200005     Document Type: Review

References (46)

1. Hattersley AT, Pearson ER. Pharmacogenetics and beyond: the interaction of the interaction of therapeutic response, B-cell physiology and genetics in diabetes. Endocrinology. 2006;143:2657-63.
2. Gloyn AL, Pearson ER, Anticliff JF, Proks P, Bruining GJ, Slingerland AS, et al. Activating muttions in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004;350:1838-49.
3. Shield JPH. Neonatal diabetes: how research unraveling the genetic puzzle has both widened our understanding of pancreatic development whilst improving children's quality of life. Horm Res. 2007;67:77-83.
4. Iafusco D, Stazi MA, Cotichini R, Cotellessa M, Martinucci ME, Mazzella M, et al., and the early onset diabetes study group of the Italian Society of Pediatric Endocrinology and Diabetology. Permanent diabetes in the first year of life. Diabetologia. 2002;45:798-804.
5. von Muhlendahl KE, Herkenhoff H. Long-term course of neonatal diabetes. N Engl J Med. 1995;333:704-8.
6. Shield JPH, Gardner RJ, Wadswoth EJK, Whiteford ML, James RS, Robinson DO, et al. Aetiopathology and genetic basis of neonatal diabetes. Arch Dis Child. 1997;76: F39-42.
7. Slingerland AS, Hattersley AT. Mutations in the Kir6.2 subunit of the KATP channel and permanent neonatal diabetes: new insights and new treatment. Ann Med. 2005;37:186-95.
8. Polak M, Cavé H. Neonatal diabetes mellitus: a disease linked to multiple mechanisms. Orphanet J Rare Dis Mar. 2007;2:12.
9. Temple IK, Gardner RJ, Mackay DJG, Barber JCK, Robinsons DO, Shield JPH. Transient neonatal diabetes. Widening the understanding of the etiopathogenesis of diabetes. Diabetes. 2000;49:1359-66.
10. Schiff D, Cole E, Stern L. Metabolic and growth patterns in transient neonatal diabetes. N Engl J Med. 1972;287:119-22.
11. Metz C, Cavé H, Bertrand AM, Deffert C, Gueguen-Giroux B, Czernichow P, et al, the NDM French Study Group. Neonatal diabetes mellitus: chromosomal analysis in transient and permanent cases. J Pediatr. 2002;141:483-9.
12. Ma D, Shield JPH, Leclerc I, Knauf C, Buecelin R, Rutter GA, et al. Impaired glucose homeostasis in transgenic mice expressing the human transient neonatal diabetes mellitus locus, TNDM. J Clin Invest. 2004;114:339-48.
13. Edghill EL, Dix RJ, Flanaghan SE, Bingley PJ, Hattersley AT, Ellard S, et al. HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes. 2006;55:1895-8.
14. Temple IK, James RS, Crolla JA, Sitch FL, Jacobs PA, Howell WM, et al. An imprinted gene(s) for diabetes? Nat Genet. 1995;9:110-2.
15. Whiteford ML, Narendra A, White MP, Cooke A, Wilkinson AG, Robertson KJ, et al. Paternal uniparental disomy for chromosome 6 causes transient neonatal diabetes. J Med Genet. 1997;34:67-168.
16. Pivinick EK, Qumisiyech MB, Tharapel AT, Summitt JB, Wilroy RS. Partial duplication of the long arm of chromosome 6: a clinically recognizable syndrome. J Med Genet. 1990;27:523-6.
17. Gardner RJ, Mackay DJ, Mungall AJ, Polychronakos C, Siebert R, Shield JP, et al. An imprinted locus associated with transient neonatal diabetes mellitus. Hum Mol Genet. 2000;9:589-96.
18. Temple IK, Gardner RJ, Robinson DO, Kibirige MS, Fergusson AW, Baum JD, et al. Further evidence for an imprinted gene for neonatal diabetes localized to chromosome 6q22-q23. Hum Mol Genet. 1996;5:1117-21.
19. Arima T, Drewell RA, Arney KL, Inoue J, Makita Y, Hata A, et al. A conserved imprinting control region at the HYMAI/ZAC domain is implicated in transient neonatal diabetes mellitus. Hum Mol Genet. 2001;10:1475-83.
20. Massa O, Iafusco D, D'Amato E, Gloyn AL, Hattersley AT, Pasquino B, et al., Barbetti F and Early Onset Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetology. KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum Mutat. 2005;25:22-7.
21. Sagen JV, Raeder H, Hathoud E, Shehadeh N, Gudmundsson K, Baevre H et al. Permanent neonatal diabetes due to mutations in the KCNJ11 encoding Kir6.2. Patient characteristics and initial response to sulphonylurea therapy. Diabetes. 2004:53:2713-8.
22. Vaxilaire M, Populaire C, Busiah K, Cavé H, Gloyn AL, Hattersley AT, et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes. 2004;53:2719-22.
23. Hattersley AT. Molecular genetics goes to the diabetes clinic. Clin Med. 2005;5:476-81.
24. Slingerland AS, Hattersley AT. Mutations in the Kir6.2 subunit of the KATP channel and permanent neonatal diabetes: new insights and new treatment. Ann Med. 2005;37:186-95.
25. Proks P, Girard C, Haider S, Gloyn AL, Hattersley AT, Sansom SP, et al. A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome. EMBO Rep. 2005;6:470-5.
26. Hattersley AT, Aschroft FM. Activating mutations in the Kir6.2 and neonatal diabetes.New clinical syndromes, new scientific insights, and new therapy. Diabetes. 2005;54:2503-13.
27. Hussain K. Congenital hyperinsulinism. Semin Fetal Neonatal Med. 2005;10:369-76.
28. Proks P, Arnold AL, Bruining J, Girard C, Flanagan SE, Larkin B, et al. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. J Hum Mol Genet. 2006;15:1793-800.
29. Babenko AP, Polak M, Cavé H, Busiah K, Czernichow P, Scharfmann R, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellius. N Engl J Med. 2006;355:456-66.
30. Vaxillaire M, Dechaume A, Busiah K, Cavé H, Pereira S, Scharfmann R, et al., and the SUR1-Neonatal Diabetes Study Group. New ABCC8 mutations in relapsing neonatal diabetes and clinical features. Diabetes. 2007;56:1737-41.
31. Stoy J, Edghill EL, Flanagan SE, Ye Honggang, Paz VP, Pluzhnikov A, et al., for the Neonatal Diabetes International Collaborative Group. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci USA. 2007;18:15040-4.
32. Shoelson S, Haneda M, Blix P, Nanjo A, Sanke T, Inouye K, et al. Three mutant insulins in man. Nature. 1983;302:540-3.
33. Nanjo K, Sanke T, Miyano M, Okai K, Sowa R, Kondo M, et al. Diabetes due to secretion of a structurally abnormal insulin (insulin Wakayama). Clinical and functional characteristics of [LeuA3] insulin. J Clin Invest. 1986;77:514-9.
34. Nanjo K, Kondo M, Sanke T, Nishi M. Abnormal insulinemia. Diabetes Res Clin Pract. 1994;24 suppl:S135-41.
35. Edghill EL, Flanagan SE, Patch AM, Boustred C, Parrish A, Shields B, et al., the Neonatal Diabetes Internacional Collaborative Group, Hattersley AT, Ellard S. Insulin mutation screening in 1044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabete but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes. 2007;Dec 27 [Epud ahead of print].
36. Njolstad PR, Sagen JV, Cuesta-Munoz A, Bjorkhaug L, Massa O, Barbetti F, et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med. 2001;344:1588-92.
37. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WI, Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet. 1997;15:106-10.
38. Schwitzgebel VM, Mamin A, Brun T, Ritz-Laser B, Zaiko M, Maret, A et al. Agenesis of the human pancreas due to decreased half-life of insulin promoter factor 1. J Clin Endocrinol Metab. 2003;88:4398-406.
39. Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, poliendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet. 2002;39:537-45.
40. Delepine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C. EIF2AK3, encoding translation iniciation factor 2-a kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet. 2000;25:406-9.
41. Sellick GS, Barker KT, Scolte-Dijkstra I, Fleischmann C, Coleman RJ, Garrett C, et al. Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat Genet. 2004;36:I301-5.
42. Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes due to an activating mutation in Kir6.2. J Clin Endocrinol Metab. 2004;89:5504-7.
43. Tonini G, Bizzarri C, Bonfanti R, Vanelli M, Cerutti F, Faleschini E, et al. Sulfonylurea treatment outweights insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (Kir6.2) gene. Diabetologia. 2006;49:2210-3.
44. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, et al., the Neoantal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylreas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355:467-77.
45. Gurgel LC, Crispim F, Noffs MH, Belzunces E, Rahal MA, Moisés RS. Sulfonylrea treatment in permanent neonatal diabetes due to G53D mutation in the KCNJ11 gene: improvement in metabolic control and neurological function. Diabetes Care. 2007;30:e108.
46. Gloyn AL, Ellard S. Defining the genetic aetiology of monogenic diabetes can improve treatment. Expert Opin Pharmacother. 2006;7:1759-67.